On April 11, 2022, the Board of Directors of Sera Prognostics, Inc. appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022, as a director to the Board to serve as a Class I Director with a term expiring at the Company's 2022 annual meeting of stockholders. Dr. Barlow has served as Chief Executive Officer of Jane Barlow & Associates, LLC, a consulting firm focused on value-based health care services, since January 2017, and Executive Vice President and Chief Clinical Officer at Real Endpoints, a data, analytics, and advisory firm, since January 2017. She currently serves on the board of directors of ContraFect Corp., a publicly traded biotechnology company, and Viracta Therapeutics, Inc., a publicly traded precision oncology company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.96 USD | +1.94% | +1.63% | +66.56% |
Mar. 28 | Sera Prognostics Insider Sold Shares Worth $727,853, According to a Recent SEC Filing | MT |
Mar. 27 | Sera Prognostics Insider Sold Shares Worth $364,484, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.56% | 317M | |
+12.35% | 16.62B | |
0.00% | 6.72B | |
-13.10% | 2.76B | |
-15.14% | 2.59B | |
-35.56% | 1.59B | |
-2.27% | 1.18B | |
-11.55% | 1.06B | |
-11.60% | 871M | |
-6.67% | 859M |
- Stock Market
- Equities
- SERA Stock
- News Sera Prognostics, Inc.
- Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director